The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citationIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Self-citationCheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Self-citationAcquired mutations in TET2 are common in myelodysplastic syndromes
Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 680
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 552
Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., et al. (2011) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 383
Self-citationDNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 355
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Self-citationLubbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02933.x · Cited by 224
Smith, A. E., Mohamedali, A. M., Kulasekararaj, A., Lim, Z., Gäken, J., Lea, N. C., Przychodzen, B., Mian, S. A., Nasser, E. E., Shooter, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 224
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
Self-citationRaj, K. K., John, A. M., Ho, A. Y. L., Chronis, C., Khan, S. N., Samuel, J., Pomplun, S., Thomas, N. S. B., & Mufti, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404796 · Cited by 146
Nibourel, O., Kosmider, O., Cheok, M. H.-C., Boissel, N., Renneville, A., Philippe, N., Dombret, H., Dreyfus, F., Quesnel, B., Geffroy, S., et al. (2010) · Blood · doi:10.1182/blood-2009-07-234484 · Cited by 140
Self-citationKantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Follo, M. Y., Finelli, C., Mongiorgi, S., Clissa, C., Bosi, C., Testoni, N., Chiarini, F., Ramazzotti, G., Baccarani, M., Martelli, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907109106 · Cited by 114
Moon, J. H., Kim, S. N., Kang, B. W., Chae, Y. S., Kim, J. G., Baek, J. H., Park, J. H., Song, M. K., Chung, J. S., Won, J.-H., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0921-5 · Cited by 30
Cited by
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Role of TET enzymes in DNA methylation, development, and cancer
Rasmussen, K. D., & Helin, K. (2016) · Genes & Development · doi:10.1101/gad.276568.115 · Cited by 1,040
Epigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 493
Bejar, R., Stevenson, K. E., Caughey, B., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G., Steensma, D. P., Ritz, J., Soiffer, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Self-citation
Metadata
- Authors
- Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V, Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V, Raynaud, S., Preudhomme, C., Adès, L., Fenaux, P., Fontenay, M., & (GFM), O. B. O. T. G. F. D. M.
- Venue
- Leukemia
- Published
- 2011-04-15
- Volume
- 25
- Issue
- 7
- Pages
- 1147-1152
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2081895311
- Cited by
- 471
- References
- 28
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.